Concurrent cisplatin, paclitaxel, and radiotherapy as preoperative treatment for patients with locoregional esophageal carcinoma

✍ Scribed by Susan G. Urba; Mark B. Orringer; Mark Ianettonni; James A. Hayman; Hayasaka Satoru

• Publisher: John Wiley and Sons
• Year: 2003
• Tongue: English
• Weight: 87 KB
• Volume: 98
• Category: Article
• ISSN: 0008-543X
• DOI: 10.1002/cncr.11759

✦ Synopsis

Abstract

BACKGROUND

A Phase II trial was conducted at the University of Michigan to determine the efficacy of a preoperative regimen of concurrent cisplatin, paclitaxel, and radiation for patients with locoregional esophageal carcinoma.

METHODS

Sixty‐nine patients with esophageal carcinoma were treated with cisplatin 75 mg/m^2^ on Day 1, paclitaxel 60 mg/m^2^ on Days 1, 8, 15, and 22, and radiation 1.5 Gray (Gy) twice per day on Days 1–5, 8–12, and 15–19, for a total dose of 45 Gy. Transhiatal esophagectomy was performed on approximately Day 50.

RESULTS

The treatment regimen was well tolerated. Only 13% of patients developed Grade 3 or 4 neutropenia and 17% of patients required feeding tubes. Ninety percent of all patients had complete tumor resection at the time of surgery. Nineteen percent of patients achieved a complete histologic response in the resected specimen. The median survival period was 24 months. One‐, 2‐, and 3‐year survival probabilities were 75%, 50%, and 34%, respectively.

CONCLUSIONS

This cisplatin‐based preoperative regimen, which contained paclitaxel rather than 5‐fluorouracil, was well tolerated. The survival data compared favorably with other previously reported combinations. This regimen is a reasonable preoperative approach for patients with localized esophageal carcinoma. Cancer 2003. © 2003 American Cancer Society.